Pharmaceuticals Biotechnology and Life Sciences
More
-
NEW YORK, April 5- A federal judge on Friday ordered the U.S. Food and Drug Administration to make "morning-after" emergency contraception pills available without a prescription to all girls of reproductive age and criticized the Obama administration for interfering with the process for political purposes.
-
NEW YORK, April 5- A federal judge on Friday ordered the U.S. Food and Drug Administration to make "morning-after" emergency contraception pills available without a prescription to all girls of reproductive age and criticized the Obama administration for interfering with the process for political purposes.
-
CAMBRIDGE, Mass.-- InVivo Therapeutics Holdings Corp. said Friday that the Food and Drug Administration will allow it to start human trials of an experimental product that is intended to treat spinal cord injuries. The Cambridge, Mass., company said there are no FDA- approved treatments that intervene directly in the spinal cord following an injury.
-
NEW YORK-- Shares of Rigel Therapeutics Inc. lost more than a third of their value Friday on mixed results from a late-stage clinical trial of a rheumatoid arthritis drug the company helped develop.
-
Richard Bernstein, Richard Bernstein Advisors CEO, offers strategies for where to put your money now.
-
*Rigel shares slump 33 pct, AstraZeneca little changed. LONDON, April 5- AstraZeneca's experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial, leaving the future of one of the group's few advanced pipeline products uncertain.
-
LONDON, April 5- AstraZeneca's experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial, leaving the future of one of the group's few advanced pipeline products uncertain.
-
1999: Teva Pharmaceutical Industries Ltd receives FDA approval to market Plan B, the first emergency contraceptive drug for prescription-only use in the United States. 2005: Reproductive-rights groups file lawsuit in Brooklyn federal court seeking to force FDA to respond to their petition.
-
NEW YORK-- Vertex Pharmaceuticals Inc. said Friday it will work with Bristol-Myers Squibb Co. to study a potential hepatitis C treatment regimen that includes Bristol-Myers Squibb's drug daclatasvir and Vertex's VX-135. Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States.
-
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
-
LONDON, April 4- After a lengthy fight, Swiss drugmaker Roche Holding AG said it had agreed to hand over data from all clinical trials of its best-selling flu drug Tamiflu to a group of outside researchers. Sales of the drug hit close to $3 billion in 2009 due to the H1N1 swine flu pandemic, although they have since declined.
-
ATLANTA-- CryoLife Inc. said Thursday that the Food and Drug Administration cleared a new version of its HeRO graft. CryoLife said the new version of the graft has an adaptor that allows physicians to combine the HeRO with other dialysis access grafts. Shares of CryoLife rose 19 cents, or 3.2 percent, to $6.06 in afternoon trading.
-
The product launches include Medivation Inc.' s prostate cancer pill Xtandi and Biogen Idec Inc.' s multiple sclerosis pill Tecfidera, along with clinical trial data on Gilead Sciences Inc.' s latest hepatitis C regimen.
-
NEW YORK-- Shares of Navidea Biopharmaceuticals Inc. rose Thursday after the company reported favorable new clinical trial results for its imaging agent Lymphoseek. The Food and Drug Administration approved Lymphoseek March 13 to help doctors locate lymph nodes in patients with breast cancer and skin cancer.
-
Valeant Pharmaceuticals International Inc. said Thursday that a newly approved generic version of one of its drugs could significantly reduce its profits this year.
-
"Drug stocks can rally in any environment," Cramer said, highlighting three companies in particular.
-
LONG BEACH, Calif.-- Obagi Medical Products Inc. said Wednesday that Canadian drugmaker Valeant Pharmaceuticals boosted its offer to buy the dermatology products maker, topping a bid made a day ago by a German rival.
-
*Elan welcomes Irish Takeover Panel deadline for bid. DUBLIN, April 3- U.S. investment firm Royalty Pharma, which is considering a $6.6- billion bid for Irish drugmaker Elan, must make a firm offer by May 10 or walk away, Ireland's Takeover Panel said on Wednesday.
-
*Elan welcomes Irish Takeover Panel deadline for bid. DUBLIN, April 3- U.S. investment firm Royalty Pharma, which is considering a $6.6- billion bid for Irish drugmaker Elan, must make a firm offer by May 10 or walk away, Ireland's Takeover Panel said on Wednesday.
-
LONDON, April 3- AstraZeneca boosted its early-stage pipeline of experimental heart drugs on Wednesday by buying privately held U.S. biotechnology company AlphaCore Pharma, which is developing a new type of cholesterol medicine.